Verastem Oncology Highlights Promising KRAS G12D Inhibitor VS-7375 at AACR Annual Meeting 2026

Verastem Oncology has announced multiple abstracts accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. The accepted abstracts include preclinical data for the investigational asset VS-7375, an oral, KRAS G12D (ON/OFF) inhibitor in clinical development for pancreatic, lung, colorectal, and other cancers harboring a G12D mutation. The data highlight VS-7375's superior efficacy across pre-clinical models of G12D mutated cancers.